Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect